These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9239402)

  • 1. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.
    Boonmark NW; Lou XJ; Yang ZJ; Schwartz K; Zhang JL; Rubin EM; Lawn RM
    J Clin Invest; 1997 Aug; 100(3):558-64. PubMed ID: 9239402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lysine-binding function of Lp(a).
    Boonmark NW; Lawn RM
    Clin Genet; 1997 Nov; 52(5):355-60. PubMed ID: 9520126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice.
    Lou XJ; Boonmark NW; Horrigan FT; Degen JL; Lawn RM
    Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12591-5. PubMed ID: 9770530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10.
    Belczewski AR; Ho J; Taylor FB; Boffa MB; Jia Z; Koschinsky ML
    Biochemistry; 2005 Jan; 44(2):555-64. PubMed ID: 15641780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus.
    Hughes SD; Lou XJ; Ighani S; Verstuyft J; Grainger DJ; Lawn RM; Rubin EM
    J Clin Invest; 1997 Sep; 100(6):1493-500. PubMed ID: 9294116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenesis in transgenic mice expressing human apolipoprotein(a).
    Lawn RM; Wade DP; Hammer RE; Chiesa G; Verstuyft JG; Rubin EM
    Nature; 1992 Dec; 360(6405):670-2. PubMed ID: 1465128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein(a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site.
    Anglés-Cano E; Rojas G
    Biol Chem; 2002 Jan; 383(1):93-9. PubMed ID: 11928826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation.
    Bas Leerink C; Duif PF; Gimpel JA; Kortlandt W; Bouma BN; van Rijn HJ
    Thromb Haemost; 1992 Aug; 68(2):185-8. PubMed ID: 1412165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
    Callow MJ; Verstuyft J; Tangirala R; Palinski W; Rubin EM
    J Clin Invest; 1995 Sep; 96(3):1639-46. PubMed ID: 7657833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The identification and significance of a Thr-->Pro polymorphism in kringle IV type 8 of apolipoprotein(a).
    Prins J; Leus FR; van der Hoek YY; Kastelein JJ; Bouma BN; van Rijn HJ
    Thromb Haemost; 1997 May; 77(5):949-54. PubMed ID: 9184408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation.
    Becker L; Cook PM; Koschinsky ML
    Biochemistry; 2004 Aug; 43(31):9978-88. PubMed ID: 15287725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular accumulation of Lp(a): in vivo analysis of the role of lysine-binding sites using recombinant adenovirus.
    Hughes SD; Rubin EM
    Clin Genet; 1997 Nov; 52(5):361-6. PubMed ID: 9520127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of lipoprotein (a): growing complexities.
    Klezovitch O; Scanu AM
    Curr Opin Lipidol; 1995 Aug; 6(4):223-8. PubMed ID: 7670751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
    Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
    Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet.
    Purcell-Huynh DA; Farese RV; Johnson DF; Flynn LM; Pierotti V; Newland DL; Linton MF; Sanan DA; Young SG
    J Clin Invest; 1995 May; 95(5):2246-57. PubMed ID: 7738190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity.
    Koschinsky ML; Marcovina SM
    Curr Opin Lipidol; 2004 Apr; 15(2):167-74. PubMed ID: 15017359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of wild-type (Trp72) and mutant (Arg72) apolipoprotein(a) kringle IV-10 on the proliferation of human arterial smooth muscle cells.
    Yu H; Hong J; Wang B; Peng F; Li X; He C
    Chin Med J (Engl); 2003 May; 116(5):721-6. PubMed ID: 12875689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes.
    Klezovitch O; Edelstein C; Scanu AM
    J Clin Invest; 1996 Jul; 98(1):185-91. PubMed ID: 8690792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of the lysine-fibrin binding subsite of human plasminogen kringle 4.
    Mulichak AM; Tulinsky A
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):673-9. PubMed ID: 1966798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice.
    Grainger DJ; Kemp PR; Liu AC; Lawn RM; Metcalfe JC
    Nature; 1994 Aug; 370(6489):460-2. PubMed ID: 8047165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.